[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-failure-chronic-requiring-dialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-failure-chronic-requiring-dialysis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619956","phase-4-bisacodyl-oral-for-lowering-dysfunction-of-tenckhoff-catheter-100619956",false,"NCT07351357","Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter)","Multi-Centre Pragmatic Randomized Controlled Trial of Bowel Preparation Before Peritoneal Dialysis Catheter Insertion","BOLD","Inclusion Criteria:\n\n* aged 18 or older and need of peritoneal dialysis\n* willingness to give written consent and comply with the study protocol\n\nExclusion Criteria:\n\n* known contraindication to peritoneal dialysis\n* ongoing diarrhoea or active inflammatory bowel disease\n* participation in another interventional study within last 30 days of randomization\n* history of a psychological illness or condition that would interfere with the patient's ability to understand the requirement of the study and\u002For comply with the dialysis procedures","ALL","18 Years",{"count":20,"type":21},398,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Doctors need to insert catheter for patients who are going to have peritoneal dialysis. These peritoneal catheters can be obstructed or blocked afterward. The chance of not having smooth flow can be up to 12 and 31%. So far, constipation is one of the proposed reasons. Therefore, the study is aimed to investigate whether the preventive use of laxative before the surgery can help better improve the function of the catheter and hence better flow.",[27,28],"Renal Failure Chronic Requiring Dialysis","Peritoneal Dialysis",[30,31,32,33,34],"peritoneal dialysis","Tenckhoff catheter","laxative","bowel preparation","catheter dysfunction","NOT_YET_RECRUITING","2026-01-17",{"date":38,"type":39},"2026-01-21","ACTUAL",{"date":41,"type":21},"2026-01-12",{"date":43,"type":21},"2027-09-30",{"name":45,"class":46},"Chinese University of Hong Kong","OTHER",6,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100568090","phase-4-study-to-compare-the-outcome-of-receiving-continued-immunosuppression-versus-stopping-immunosuppression-at-6-months-to-safely-prevent-human-leukocyte-antigen-hla-sensitization-in-patients-with-late-renal-graft-failure-100568090","NCT06676696","Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","A Multi-centre, Open, Prospective, Randomized, Parallel-group, 24-month Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","Inclusion Criteria:\n\n* Patient must be able to understand and provide written informed consent\n* Patients older than 18 years who had received at least one previous renal transplant\n* Patients with a retained kidney graft failed for any reason which survived at least 3 months\n* Patients on dialysis, either hemodialysis or peritoneal dialysis. Patients can be on dialysis for a maximum of 6 months at the time of randomization, as long as the patients have taken an uninterrupted immunosuppressive regimen of calcineurin inhibitors (tacrolimus or cyclosporine) and steroids since dialysis was restarted\n* Patients already relisted or candidates to relist to deceased donor kidney transplantation according to the treating physician criteria\n* Patients taking immunosuppressants tacrolimus or cyclosporine\n* cPRA at the time of randomization ≤ 90%\n\nExclusion Criteria:\n\n* Patients who have received another solid organ transplantation (liver, lung, heart or pancreas)\n* Patients waiting for a living related \u002F unrelated kidney transplant\n* Graft survival of the failed graft lower than 3 months\n* Patients in dialysis more than 6 months at the time of randomization\n* Patients not accomplishing criteria to relist in the transplantation list according to the treating physician criteria\n* Pregnant women\n* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Patients should use one of the acceptable birth control measures recommended in the document \"Recommendations related to contraception and pregnancy testing in clinical trials\" published by the Clinical Trials Facilitation and Coordination Group (CTFG) (version 1.1, published 21\u002F09\u002F2020). Recommended birth control measures include oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, or sexual abstinence. If sexually active, the subject must have been using one of the accepted birth control methods at least one month prior to study entry.",{"count":56,"type":21},202,[24],"The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (\\> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression at 6 months.\n\nThe main question this study aims to answer is:\n\nDoes maintaining long-term immunosuppression in patients with a late renal graft failure (\\> 3 months) safely reduce the risk of HLA sensitization?\n\nTo answer this question, patients will be assigned to a control arm or investigational arm:\n\n* Patients assigned to the control arm will receive standard treatment, in which immunosuppressant treatment is withdrawn after 6 months.\n* Patients assigned to the investigatonal arm will continue immunosuppressant treatment at low doses for 2 years.\n\nPatients recruited in this clinical trial will be followed for up to 2 years. During this time, patients will visit the clinic every 3 months for checkups and tests.",[60,61,62,63,27],"Renal Failure , Chronic","Graft Failure","Graft Rejection","Allograft",[65,66,67,68,69],"Renal failure","immunosuppressor","HLA sensitization","Graft failure","Calcineurin inhibitors","RECRUITING","2024-11-05",{"date":73,"type":39},"2024-11-06",{"date":75,"type":39},"2024-01-22",{"date":77,"type":21},"2028-01-31",{"name":79,"class":46},"Hospital Universitari Vall d'Hebron Research Institute",1]